All Posts

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers...

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers such as prostate cancer and ovarian cancer Several smid-cap biopharmas are presenting data at ASCO-GU, including final results from BTAI We have also determined additional upcoming late stage trials in GU cancers in the next year   ASCO-GU 2023 starts February 16 and focuses on new and innovative findings and studies for the treatment of ge

Summary: GTHX Trilaciclib Phase 3 data in colorectal cancer is expected in February 2023 This is initial PRESERVE 1 CRC data and initial...

Originally posted 1/25/23; last updated 4/13/23 Summary: Many exciting Alzheimer's disease catalysts are coming throughout the year See...

Summary: SAVA Ph2 Open label study topline data was reported today, 1/24/23 While the data was reported as positive, the market did not...

SUMMARY Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23 The AGEN ASCO-GI23 presentation...

Summary Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23 The AGEN ASCO-GI23 presentation included expanded data from the Phase 1a/1b trial expansion cohort in MSS-CRC Key publicly available data from the presentation is provided below. Want more AGEN analysis and trade ideas? Sign up for one of our paid subscriptions HERE  and save with our current promotion Sign up for a BPIQ Pro account and get access to our BPIQ Pro post HERE , with

This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...